Patients in insulin analogues use via judicial litigation: do they use the Brazilian Public Health System (SUS)?
| Autor: | Thays Santos Mendonça, Eduardo Sérgio Silva, Mariana Linhares Pereira, Paulo Roque Obreli-Neto, Vinícius Silva Belo, Gustavo Costa Ferreira, Paula Resende Daher Chaves, Silvana Nair Leite, André Oliveira Baldoni |
|---|---|
| Jazyk: | English<br />Spanish; Castilian<br />Portuguese |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Cadernos de Saúde Coletiva, Vol 31, Iss 2 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1414-462X 1414-462x |
| DOI: | 10.1590/1414-462x202331020102 |
| Popis: | Abstract Background Studies show that among the drugs most commonly used in judicial litigation in Brazil, are those used to treat diabetes mellitus, especially insulin analogues. Objective Evaluate the use of the Unified Health System (SUS) by patients with type 1 diabetes mellitus (T1DM), who receive insulin analogues through judicial action, before and after this process. Method In a retrospective longitudinal observational study, secondary data was used from these patients in Minas Gerais, Brazil, in 2018. Socio-demographic information was collected and related to the follow-up of these patients in the SUS. The McNemar χ2 test was used to compare the proportions of the variables. Results Of the 89 patients analyzed, women (53.9%) were predominant. Most patients were aged between 20 and 39 years (52.8%), and more than half, 55.1%, use only a private health system. After the judicial action, there was a significant increase (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|